| 1.93 -0.06 (-3.02%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.34 |
1-year : | 2.52 |
| Resists | First : | 2.01 |
Second : | 2.16 |
| Pivot price | 1.95 | |||
| Supports | First : | 1.76 |
Second : | 1.47 |
| MAs | MA(5) : | 1.92  |
MA(20) : | 1.93 |
| MA(100) : | 1.97 |
MA(250) : | 1.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.5 |
D(3) : | 40.8 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 3.49 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CGTX ] has closed above bottom band by 41.8%. Bollinger Bands are 41.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2 - 2.01 | 2.01 - 2.02 |
| Low: | 1.82 - 1.84 | 1.84 - 1.85 |
| Close: | 1.91 - 1.93 | 1.93 - 1.95 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Thu, 18 Apr 2024
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's (NASDAQ:CGTX) - Seeking Alpha
Tue, 02 Apr 2024
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference - GlobeNewswire
Mon, 01 Apr 2024
Cognition to Host Virtual KOL in Mid-April - Baystreet.ca
Wed, 27 Mar 2024
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript - Yahoo Finance
Fri, 15 Mar 2024
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying - Blue Star Foods (NASDAQ:BSFC), C - Benzinga
Thu, 14 Mar 2024
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 39 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 34.1 (%) |
| Shares Short | 150 (K) |
| Shares Short P.Month | 127 (K) |
| EPS | -0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.1 % |
| Return on Equity (ttm) | -79.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -2.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|